Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer, Coupled to Extensive Translational Studies

NCT03804580 is registered in ClinicalTrials.gov with Vestre Viken Hospital Trust as lead sponsor.

NCT NCT03804580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03804580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer, Coupled to Extensive Translational Studies
Lead sponsor
Vestre Viken Hospital Trust
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2018
Completion date
December 31, 2025
Enrollment
100 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer